MAPT and Alzheimer disease: To determine the effect of AD-related tau pathology to the CSF levels of p-tau we focused on the CJD MM(V)1 cases, the largest homogeneous group available (n = 109 brains) and the one showing the least amount of prion-specific tau pathology (see above).